COMPASS Pathways has completed its New Drug Application (NDA) submission to the FDA for COMP360 psilocybin for treatment-resistant depression. This is a critical step towards potential market approval and commercialization, which the company targets for H1 2027, contingent on regulatory and DEA approvals.
COMPASS Pathways announced the completion of its New Drug Application (NDA) submission to the FDA for COMP360, its proprietary psilocybin formulation for treatment-resistant depression (TRD). This is a major regulatory milestone, signaling the company's progress towards bringing its lead investigational therapy to market. The filing is a positive development for CMPS, as it moves closer to potential commercialization, which they aim for in the first half of 2027, pending FDA approval and DEA rescheduling. For traders, this reduces regulatory uncertainty in the near term and could provide upward momentum for CMPS, while also highlighting the growing legitimacy of psychedelic-based therapies in the broader pharmaceutical landscape.